The ALS-FTD-Parkinsonism spectrum represents a continuum of neurodegenerative disorders characterized by overlapping clinical, genetic, and pathological features. This comparison matrix systematically analyzes the shared mechanisms, genetic architecture, and therapeutic targets across [Amyotrophic Lateral Sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis), [Frontotemporal Dementia (FTD) – especially the FTD-ALS spectrum](/diseases/ftd-als-spectrum), and atypical parkinsonian syndromes including [Progressive Supranuclear Palsy (PSP) – especially the corticobasal syndrome (CBS) overlap](/diseases/psp-cbd-overlap), [Corticobasal Syndrome (CBS/CBD) ](/diseases/corticobasal-syndrome), and [Multiple System Atrophy (MSA) ](/diseases/multiple-system-atrophy).
These disorders share fundamental pathogenic mechanisms including protein aggregation (TDP-43, tau, alpha-synuclein), RNA metabolism defects, nucleocytoplasmic transport dysfunction, mitochondrial dysfunction, and neuroinflammation. Understanding these shared pathways is critical for developing cross-disease therapeutic strategies and biomarkers.
The ALS-FTD-Parkinsonism spectrum represents a continuum of neurodegenerative disorders characterized by overlapping clinical, genetic, and pathological features. This comparison matrix systematically analyzes the shared mechanisms, genetic architecture, and therapeutic targets across [Amyotrophic Lateral Sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis), [Frontotemporal Dementia (FTD) – especially the FTD-ALS spectrum](/diseases/ftd-als-spectrum), and atypical parkinsonian syndromes including [Progressive Supranuclear Palsy (PSP) – especially the corticobasal syndrome (CBS) overlap](/diseases/psp-cbd-overlap), [Corticobasal Syndrome (CBS/CBD) ](/diseases/corticobasal-syndrome), and [Multiple System Atrophy (MSA) ](/diseases/multiple-system-atrophy).
These disorders share fundamental pathogenic mechanisms including protein aggregation (TDP-43, tau, alpha-synuclein), RNA metabolism defects, nucleocytoplasmic transport dysfunction, mitochondrial dysfunction, and neuroinflammation. Understanding these shared pathways is critical for developing cross-disease therapeutic strategies and biomarkers.
| Clinical Feature | ALS | FTD (bvFTD) | PSP | CBS/CBD | MSA |
|-----------------|-----|-------------|-----|---------|-----|
| Motor Neuron Disease | Core (100%) | Occasional (15%) | Rare | Rare | Rare |
| Behavioral Changes | Moderate (30%) | Core (100%) | Moderate (40%) | Moderate (50%) | Mild (20%) |
| Cognitive Decline | Variable (50%) | Core (100%) | Moderate (50%) | Moderate (60%) | Moderate (40%) |
| Parkinsonism | Rare | Rare | Core (100%) | Core (100%) | Core (100%) |
| Ocular Motor Deficit | Rare | Rare | Core (70%) | Variable | Variable |
| Dystonia | Occasional | Rare | Common (60%) | Core (70%) | Variable |
| Myoclonus | Occasional | Rare | Variable | Common (50%) | Rare |
| Ataxia | Rare | Rare | Variable | Variable | Core (60%) |
| Dysphagia | Core (90%) | Variable | Common (60%) | Common (50%) | Common (70%) |
| Urinary Dysfunction | Rare | Rare | Variable | Variable | Core (80%) |
The ALS-FTD-Parkinsonism spectrum shows significant genetic overlap, with several genes implicated across multiple conditions[@boylan2023][@goldman2023]:
| Gene | Protein | ALS | FTD | PSP | CBS | MSA | Key Mechanism |
|------|---------|-----|-----|-----|-----|-----|---------------|
| [C9orf72](/genes/c9orf72) | C9orf72 protein | +++ | +++ | + | + | + | RNA foci, DPR toxicity |
| [TARDBP](/genes/tardbp) | TDP-43 | +++ | ++ | - | + | - | RNA metabolism |
| [FUS](/genes/fus) | FUS protein | ++ | + | - | - | - | RNA binding |
| [GRN](/genes/grn) | Progranulin | + | +++ | + | ++ | - | Lysosomal function |
| [MAPT](/genes/mapt) | Tau | + | +++ | +++ | +++ | - | Microtubule stability |
| TBK1 | TANK-binding kinase 1 | ++ | ++ | - | + | - | Autophagy, inflammation |
| VCP | Valosin-containing protein | + | ++ | - | + | - | Protein quality control |
| SQSTM1 | p62 | + | + | + | + | - | Autophagy, signaling |
| ALS2 | Alsin | + | - | - | - | - | Endosomal trafficking |
| SETX | Senataxin | + | - | - | - | - | RNA processing |
| ATXN2 | Ataxin-2 | ++ | + | - | - | - | RNA binding, translation |
The [C9orf72 repeat expansion](/mechanisms/c9orf72-hexanucleotide-repeat-expansion) is the most significant genetic link across this spectrum[@renton2011][@majounie2012]:
The TDP-43 proteinopathy defines most ALS and a majority of FTD cases[@ling2013][@gabery2022]:
TDP-43 Pathology Classification:
├── ALS: ~95% of cases (sporadic and most familial)
│ └── Type B pattern (skeletal muscle, motor neurons)
├── FTD: ~50% of cases (FTLD-TDP)
│ ├── Type A (GRN mutations): Neuronal perikarya, dystrophic neurites
│ ├── Type B (C9orf72): Moderate perikarya, few neurites
│ └── Type C (Semantic variant PPA): Long dystrophic neurites
├── CBS: ~30% of cases (usually FTLD-TDP type A)
└── PSP: Rare (~10% of cases)
| Protein | ALS | FTD | PSP | CBS | MSA | Notes |
|---------|-----|-----|-----|-----|-----|-------|
| TDP-43 | +++ | +++ | + | ++ | - | Most common aggregate |
| Tau (3R) | - | + | - | + | - | Pick bodies |
| Tau (4R) | - | + | +++ | +++ | - | PSP, CBD signature |
| α-Synuclein | + | + | + | + | +++ | MSA, incidental |
| FUS | ++ | + | - | - | - | ALS-FUS cases |
RNA metabolism defects are central to ALS-FTD pathogenesis[@meyer2023]:
Defects in nuclear import/export are emerging as a key shared mechanism[@zhang2023]:
Energy metabolism impairment is common across the spectrum:
Microglial activation and innate immune responses are prominent[@gao2022][@wu2022]:
Dysfunction in protein clearance mechanisms is shared:
| Component | ALS | FTD | PSP | CBS | MSA |
|-----------|-----|-----|-----|-----|-----|
| Autophagy | ++ | ++ | ++ | ++ | +++ |
| Ubiquitin-proteasome | ++ | ++ | + | + | + |
| Lysosomal function | + | +++ | + | ++ | +++ |
| VCP mutations | + | ++ | - | + | - |
| GRN haploinsufficiency | + | +++ | - | ++ | - |
| Finding | ALS | FTD | PSP | CBS | MSA |
|---------|-----|-----|-----|-----|-----|
| Motor cortex atrophy | +++ | + | + | ++ | + |
| Frontotemporal atrophy | + | +++ | + | ++ | - |
| Midbrain atrophy | - | - | +++ | + | ++ |
| Brainstem atrophy | + | - | ++ | + | ++ |
| Cerebellar atrophy | - | - | + | + | +++ |
| Pons atrophy | - | - | ++ | - | +++ |
| Asymmetric findings | ++ | + | - | +++ | - |
| Technique | ALS | FTD | PSP | CBS | MSA |
|-----------|-----|-----|-----|-----|-----|
| DTI: Corticospinal tract | +++ | + | ++ | ++ | + |
| DTI: Frontotemporal WM | + | +++ | + | ++ | - |
| RS-fMRI: Motor network | ++ | + | ++ | +++ | + |
| RS-fMRI: Salience network | + | +++ | + | ++ | - |
| FDG-PET: Hypometabolism | Motor cortex | Frontal | Midbrain, frontal | Asymmetric | Cerebellar, brainstem |
| Biomarker | ALS | FTD | PSP | CBS | MSA | Utility |
|-----------|-----|-----|-----|-----|-----|---------|
| NfL | +++ | ++ | ++ | ++ | ++ | Disease progression |
| pNfH | +++ | + | ++ | ++ | + | Specificity |
| TDP-43 (CSF) | ++ | ++ | - | + | - | Disease activity |
| Total tau | + | + | +++ | ++ | + | PSP/CBS specificity |
| p-tau181 | + | + | ++ | ++ | - | Differential |
| α-Synuclein (SAA) | - | - | - | - | +++ | MSA diagnosis |
| Neurofilament light | +++ | ++ | ++ | ++ | ++ | Prognosis |
| Progranulin (plasma) | + | +++ | - | ++ | - | GRN carriers |
| Target | ALS | FTD | PSP | CBS | MSA | Therapeutic Approach |
|--------|-----|-----|-----|-----|-----|---------------------|
| RNA metabolism | +++ | +++ | + | + | - | ASOs, small molecules |
| Nucleocytoplasmic transport | ++ | ++ | + | + | - | Nuclear pore modulators |
| TDP-43 aggregation | +++ | +++ | + | ++ | - | Immunotherapy, ASOs |
| Tau pathology | - | + | +++ | +++ | - | Antibodies, inhibitors |
| Neuroinflammation | +++ | +++ | +++ | +++ | ++ | TREM2 agonists, anti-cytokines |
| Mitochondrial function | +++ | ++ | ++ | ++ | ++ | Antioxidants, modulators |
| Autophagy enhancement | ++ | ++ | ++ | ++ | +++ | Autophagy inducers |
| Neurotrophic support | ++ | ++ | + | + | + | Growth factors |
| Therapy | Target | ALS | FTD | PSP | CBS | Stage |
|---------|--------|-----|-----|-----|-----|-------|
| Tofersen | SOD1 | FDA approved | - | - | - | Approved |
| Lecanemab | Aβ | - | - | - | - | FDA approved (AD) |
| Tilavonemab | Tau | - | - | Phase 2 | Phase 2 | Active |
| Cinpanemab | α-Syn | - | - | - | - | Phase 2 |
| Rapamycin | mTOR/autophagy | Phase 2 | Phase 2 | Phase 2 | Phase 2 | Active |
| Gene therapy (C9orf72) | C9orf72 | Phase 1/2 | Phase 1/2 | Preclinical | - | Developing |
| Gene therapy (GRN) | Progranulin | - | Phase 1/2 | - | Preclinical | Developing |
| Drug | Original Indication | Potential Use | Mechanism |
|------|---------------------|---------------|-----------|
| Riluzole | ALS | FTD, PSP | Glutamate modulation |
| Edaravone | ALS | FTD, CBS | Antioxidant |
| Minocycline | Antibiotic | ALS, FTD | Anti-inflammatory |
| Arimoclomol | HD | ALS | HSP induction |
| Sodium phenylbutyrate | Urea cycle | ALS | ER stress reduction |
| Amantadine | Parkinson's | PSP, CBS | Dopaminergic |
| Parameter | ALS | FTD | PSP | CBS | MSA |
|-----------|-----|-----|-----|-----|-----|
| Mean onset age | 55-65 | 50-60 | 60-70 | 60-70 | 50-60 |
| Median survival | 2-4 years | 6-11 years | 5-7 years | 5-8 years | 6-9 years |
| Progression rate | Fast | Variable | Moderate | Variable | Slow-moderate |
| Primary cause of death | Respiratory failure | Complications | Falls, complications | Complications | Respiratory, autonomic |
ALS:
The [FTD-ALS spectrum](/diseases/ftd-als-spectrum) represents the strongest clinical and genetic overlap[@hardiman2017]:
The [PSP-CBD overlap](/diseases/psp-cbd-overlap) is well-established[@sieben2012]:
Priority areas for cross-disease biomarkers:
Strategic approaches:
Recommendations: